Medicus Pharma reports Q3 loss, pivots to Pfizer‑licensed cancer drug and $135 M SPAC merger for SkinJect
Medicus Pharma Ltd. posted a third‑quarter 2026 net loss of $15.2 million, narrower than the prior year, and reduced operating expenses to $14.5 million. The company said it will concentrate development on CD228V, a Pfizer‑licensed antibody‑drug conjugate for melanoma, and has entered a non‑binding LOI to merge its SkinJect subsidiary with an undisclosed SPAC at an approximately $135 million pre‑money enterprise valuation. Management highlighted a $12.0 million upfront payment to Pfizer and expects about $3 million of costs for the SkinJect program over the next two years.
Why it matters
The narrower loss and cash balance of $13.1 million give the company a limited runway, making the proposed SPAC transaction a potential source of financing but also a dilution risk for shareholders. The Pfizer partnership could add clinical value if CD228V demonstrates efficacy, but the upfront payment and development funding offset cash reserves.
Key facts
- 1Q3 2026 net loss was $15.2 million, compared with $16.0 million in Q3 2025. investing.com
- 2Operating expenses for Q3 2026 were $14.5 million, down from $15.4 million in Q3 2025. investing.com
- 3Nine‑month net loss (nine months ended September 30, 2026) was $35.9 million. investing.com
- 4Combined cash and restricted cash as of September 30, 2026 totaled $13.1 million ($5.0 million unrestricted and $8.1 million restricted). investing.com
- 5Medicus announced a non‑binding LOI for SkinJect to merge with an undisclosed SPAC at an approximately $135 million pre‑money enterprise valuation. investing.com
- 6The company projects about $3 million in costs for the SkinJect Gorlin syndrome program over the next two years. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.